eng Science and Education Publishing American Journal of Medical Case Reports 2374-216X 2023-04-19 11 4 81 83 10.12691/ajmcr-11-4-5 AJMCR20231145 article Samer Barahmeh samer.barahmeh@iah.ps 1 2 Oadi N. Shrateh 3 Afnan W.M. Jobran 3 Akram Karmeh 4 Maysam Hamarsheh 4 Salsabeel Rajab 4 Assistant Professor, Faculty of Medicine, Al-Quds University, Jerusalem, Palestine Faculty of medicine, Al-Quds University, Jerusalem, Palestine Department of Hematology, Al-Istishari Arab Hospital, Ramallah, Palestine Introduction: An uncommon autosomal recessive genetic condition called congenital factor VII deficiency (FVIID) exists. This deficit has a wide range of clinical signs and symptoms. Pregnant women with congenital FVIID face a high risk of bleeding during and after delivery. The most popular kind of replacement therapy for FVIID is recombinant factor VIIa. For pregnant women with congenital FVIID, no standardized diagnosis or treatment strategy has been developed. Case presentation: We discuss the clinical background of a woman who was believed to have congenital FVIID when she was pregnant. The pregnant woman received recombinant factor VIIa as a preventative treatment when her cervical opening was complete. She delivered a live baby successfully without any difficulties or complications, including postpartum hemorrhage, neonatal defects, etc. Discussion and Conclusion: Pregnant women with hereditary FVIID who are at high risk of bleeding can effectively lower the incidence of postpartum hemorrhage by receiving recombinant factor VIIa as part of their prenatal care. http://pubs.sciepub.com/ajmcr/11/4/5/ajmcr-11-4-5.pdf congenital factor VII deficiency diagnosis and treatment plan pregnancy perinatal management case report